U.S. government to study allergic reactions to COVID vaccines

2 weeks ago 5

The National Institutes of Health said Wednesday that it started a clinical study assessing allergic reactions to the mRNA COVID-19 vaccines developed by Moderna Inc. MRNA, +0.25% and BioNTech SE BNTX, -2.42% /Pfizer Inc. PFE, -0.25%. The aim is to understand who is at increased risk, including people with a history of allergic reactions or those who have been diagnosed with a mast cell disorder. (Mast cells are part of the body's immune system. When those cells mutate, it can cause one of several rare disorders.) The Phase 2 clinical trial, which is being funded by the National Institute of Allergy and Infectious Diseases, will enroll 3,400 adults who fit one of three categories: people who have previously reported a severe allergic reaction to food, insects, or a medication; people who have been diagnosed with a mast cell disorder; or individuals without a history of either. The Centers for Disease Control and Prevention says that anaphylaxis as a result of a COVID-19 vaccine occurs in up to 5 people out of every 1 million who have been vaccinated. These events "almost always" occur within 30 minutes of receiving the shot.

Read Entire Article
Sponsor Ads